United States · Financial press · Investor's Business Daily
Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday. The post Lilly's Reta Trounces Novo…
Read the full article on Investor's Business Daily Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)
